Healthcare
Leaders advancing medicine, biotechnology, care delivery and health institutions.
India Clears Takeda’s QDENGA, Opening a New Test of Dengue Prevention
India’s regulator has authorized Takeda’s two-dose QDENGA vaccine for people aged four to 60, creating a new prevention option in one of the countries most exposed to dengue.
Ritesh Agarwal Has Taken PRISM Back to the IPO Gate. Investors Will Price the Quality of OYO's Profit
A InfluenceAsia examination of how Ritesh Agarwal is turning PRISM's renewed move towards a large Indian public offering after restructuring OYO, adding Motel 6 and improving reported profitability into a test of economics, execution and durable leadership.
Reshma Kewalramani Broadened Vertex Beyond Cystic Fibrosis. Launch Economics Are the Next Clinical Test
Reshma Kewalramani has placed high-value rare-disease medicines, internally discovered small molecules, gene editing and disciplined reinvestment of cystic-fibrosis cash flow at the centre of the strategy. The next phase will test capital discipline, execution and durability across Asia.
Ugur Sahin Has Given BioNTech a EUR16.8 Billion Runway. Six Cancer Readouts Must Now Set Its Direction
BioNTech retains EUR16.8 billion in cash and securities as it approaches six late-stage readouts. Ugur Sahin must convert scientific breadth into a focused cancer business.
Nithin Kamath Is Turning Zerodha’s Profits Into Patient Capital. Rainmatter Needs Portfolio Accountability
Rainmatter has expanded from fintech partnerships into a broad portfolio and a foundation supporting climate and livelihoods. Nithin Kamath must show how patient capital learns, recycles returns and remains accountable when it avoids board seats and fixed exits.
Feng Zhang Won $34.5 Million for Paediatric Epilepsy Editing. A Shared Platform Must Defeat Rare-Disease Economics
Feng Zhang’s ARPA-H-backed PERC consortium targets two severe childhood epilepsies first. Its real value will be whether one platform can lower the cost of treating many ultra-rare diseases.
Demis Hassabis Moved DeepMind Deeper Into the Laboratory. Scientific AI Needs a Verification Business Model
Demis Hassabis is building a wider scientific-AI stack around AlphaGenome and Co-Scientist. The opportunity is large, but laboratories need reproducible gains rather than fluent novelty.
Chuan He Connected Diet, RNA Marks and Early Immunity. Product Builders Must Separate Signal From Platform
Chuan He’s latest research brings RNA regulation into early-life immunity, learning and development. The opportunity is broad, but commercial claims must stay behind causal evidence.
